ABSTRACT
BACKGROUND: There is no official leprosy register in France. The last epidemiological survey on leprosy in metropolitan France was done between 1995 and 1998. We performed a new epidemiological study of leprosy in metropolitan France in 2009 and 2010. PATIENTS AND METHODS: We contacted 85 dermatology and infectious disease units by e-mail or by telephone in order to determine the number of leprosy patients either being followed up or newly diagnosed in 2009 and 2010. RESULTS: The response rate was 87%. In 2010, 127 patients were being followed up in metropolitan France, mostly at dermatology units (78%). Seventy-five patients were on anti-bacillary treatment and the prevalence was 0.011/10,000. There were 39 new cases diagnosed in 2009 and 2010 (mean 19 cases/year) (low case-detection rate: 0.003 per 10,000 inhabitants). Among the new cases, seven patients (18%) were of French origin, with two from metropolitan France and five from French overseas territories. DISCUSSION: Our study confirms the persistence of imported leprosy in France and shows no significant decrease in the number of new cases since 1998 (19 vs. 18 new cases/year) or in disease prevalence (0.013 vs. 0.011 per 10,000 inhabitants). This prevalence is very far removed from the one per 10,000 inhabitants proposed by the World Health Organization as the criteria for endemic disease. Most patients in our survey were immigrants (82%). Lepromatous forms (46%) were more frequent than the tuberculoid forms (33%). All patients had either travelled to or lived in areas of high leprosy prevalence, including metropolitan subjects. CONCLUSION: Leprosy remains present in metropolitan France, and it is still important to continue teaching about it at medical faculties in order to ensure diagnosis of new patients as early as possible.
Subject(s)
Leprosy/epidemiology , Adolescent , Adult , Africa South of the Sahara/ethnology , Aged , Asia, Western/ethnology , Child , Dermatology , Emigrants and Immigrants/statistics & numerical data , Female , France/epidemiology , Health Surveys , Hospital Departments/statistics & numerical data , Hospitals, University/statistics & numerical data , Humans , Indian Ocean Islands/ethnology , Infectious Disease Medicine , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Leprosy/ethnology , Male , Middle Aged , Prevalence , Retrospective Studies , South America/ethnology , Travel , Urban Population/statistics & numerical data , Young AdultABSTRACT
BACKGROUND: With 254,525 new cases reported in 2007, leprosy is the worlds' second most widespread form of mycobacteriosis. According to the WHO, eradication of leprosy as a public health problem (defined by less than one case per 10,000 people) has been globally achieved. High endemic zones, however, still subsist. Leprosy rates among children, which reflect a country's endemic level, ranged from 0.55 to 19.2 % in 2006. Due to world population migrations, cases of leprosy are now seen in mainland France, in both children and adults. PATIENTS AND METHODS: We describe three leprosy patients aged under 15 years treated at the Dermatology Unit of Saint Louis Hospital between 1st January 2002 and 31st December 2008. The three cases described account for 3 % of new patients treated for leprosy at Saint Louis Hospital over this 7-year period. All were born in an endemic country. Lesions appeared 18 months after arrival in France in two cases and clinical diagnosis was made in only one case. Due to absence of sensory loss in the lesions, diagnosis was reliant upon histopathological examination in two cases. CONCLUSION: Leprosy should be suspected in children from endemic countries presenting skin lesions, particularly hypochromic lesions, even if there is no sensory loss, regardless of how long they have been living in France.
Subject(s)
Leprosy/diagnosis , Adolescent , Adrenal Cortex Hormones/therapeutic use , Age of Onset , Biopsy , Brazil/ethnology , Child , Drug Therapy, Combination , Endemic Diseases , Female , France/epidemiology , Guinea/ethnology , Humans , India/ethnology , Leprosy/drug therapy , Leprosy/epidemiology , Leprosy/pathology , Male , Retrospective Studies , Rifampin/therapeutic use , Skin/pathologySubject(s)
Clofazimine/administration & dosage , Clofazimine/therapeutic use , Dapsone/administration & dosage , Dapsone/therapeutic use , Leprostatic Agents/administration & dosage , Leprostatic Agents/adverse effects , Leprostatic Agents/therapeutic use , Leprosy, Borderline/drug therapy , Leprosy, Tuberculoid/drug therapy , Leprosy, Lepromatous/drug therapy , Leprosy/drug therapy , Drug Hypersensitivity/etiology , Drug Therapy, Combination/therapeutic use , Rifampin/administration & dosage , Rifampin/adverse effects , Rifampin/immunology , Rifampin/therapeutic use , Sulfonamides/administration & dosage , Sulfonamides/therapeutic use , Thrombocytopenia/immunology , Thrombocytopenia/chemically inducedABSTRACT
The authors studied 70 leprosy patients and 20 normal individuals, comparing the traditional sera collection method and the finger prick blood with the conservation on filter paper for specific antibodies against the native phenolic glycolipid-I (PGL-I) from Mycobacterium leprae. The finger prick blood dried on filter paper was eluated in phosphate buffer saline (PBS) containing 0.5% gelatin. The classical method for native PGL-I was performed for these eluates, and compared with the antibody determination for sera. It was observed that there is a straight correlation comparing these two methods; although the titles found for the eluates were lower than those obtained for serology. This blood collection method could be useful for investigation of new leprosy cases in field, specially in contacts individuals.
Subject(s)
Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Blood Specimen Collection/methods , Glycolipids/blood , Leprosy/immunology , Mycobacterium leprae/immunology , Adolescent , Adult , Aged , Antigens, Bacterial/blood , Enzyme-Linked Immunosorbent Assay , Female , Humans , Leprosy/blood , Linear Models , Male , Middle AgedABSTRACT
Primary and secondary dapsone resistance were studied among lepromatous patients living in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris. Four hundred fifteen biopsies were taken from clinically active and bacteriologically positive (bacterial index greater than 2) patients in the 6-year period of 1980-1985. Among these, 280 biopsies that contained 5 x 10(4) acid-fast bacilli per ml with a morphological index of at least 0.10 were inoculated into the mouse foot pad, and 229 harbored infective Mycobacterium leprae. Among the 129 infective M. leprae isolated from new cases, 54% had some degree of dapsone resistance, a low degree being prominent in all cases. Among the 100 infective M. leprae isolated from relapsed cases, 79% had a high or an intermediate degree of dapsone resistance. The annual incidence of secondary dapsone resistance was estimated to be about 0.55% in Guadeloupe.